title: Genotype-phenotype correlation and frequency of the 3199del6 cystic fibrosis mutation among I148T carriers: results from a collaborative study.
abstract: OBJECTIVE
  We expect that the mutation panel currently recommended for preconception/prenatal CF carrier screening will be modified as new information is learned regarding the phenotype associated with specific mutations and allele frequencies in various populations. One such example is the I148T mutation, originally described as a severe CF mutation. After implementation of CF population-based carrier screening, we learned that I148T exists as a complex allele with 3199del6 in patients with clinical CF, whereas asymptomatic compound heterozygotes for I148T and a second severe CF mutation were negative for 3199del6.
  
  
  METHODS
  We performed reflex testing for 3199del6 on 663 unrelated specimens, including I148T heterozygotes, compound heterozygotes, and a homozygous individual.
  
  
  RESULTS
  Less than 1% of I148T carriers were also positive for 3199del6. Excluding subjects tested because of a suspected or known CF diagnosis or positive family history, 0.6% of I148T-positive individuals were also positive for 3199del6. We identified 1 I148T homozygote and 6 unrelated compound heterozygous individuals with I148T and a second CF variant (2 of whom also carried 3199del6). In addition, one fetus with echogenic bowel and one infertile male were heterozygous for I148T (3199del6 negative).
  
  
  CONCLUSIONS
  Reflex testing for 3199del6 should be considered whenever I148T is identified. Reflex testing is of particular importance for any symptomatic patient or whenever one member of a couple carries a deleterious CF mutation and the other member is an I148T heterozygote. Further population data are required to determine if I148T, in the absence of 3199del6, is associated with mild or atypical CF or male infertility.
authors.affiliation: Department of Medical Genetics, Henry Ford Hospital, Detroit, Michigan 48202, USA.
authors.forename: K G
authors.initials: KG
authors.lastname: Monaghan
authors.forename: W E
authors.initials: WE
authors.lastname: Highsmith
authors.forename: J
authors.initials: J
authors.lastname: Amos
authors.forename: V M
authors.initials: VM
authors.lastname: Pratt
authors.forename: B
authors.initials: B
authors.lastname: Roa
authors.forename: M
authors.initials: M
authors.lastname: Friez
authors.forename: L L
authors.initials: LL
authors.lastname: Pike-Buchanan
authors.forename: I M
authors.initials: IM
authors.lastname: Buyse
authors.forename: J B
authors.initials: JB
authors.lastname: Redman
authors.forename: C M
authors.initials: CM
authors.lastname: Strom
authors.forename: A L
authors.initials: AL
authors.lastname: Young
authors.forename: W
authors.initials: W
authors.lastname: Sun
mesh_terms: D003550:Cystic Fibrosis / Q000235:genetics*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D004252:DNA Mutational Analysis; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D008297:Male; D009154:Mutation; D010641:Phenotype
chemical_list: C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator